European Psychiatry - Volume 33 - March 2016

16 / 812

Available online at
ScienceDirect
24th European Congress of Psychiatry
State-of-the-art
SA01
Psychosocial intervention in
schizophrenia
T. Wykes
Institute of Psychiatry – Psychology and Neuroscience – KCL,
Psychology, London, United Kingdom
Psychological treatments aimed at symptoms or behaviours that
impede recovery now have a relatively strong database but it is not
clear which treatments are more effective and when they should
be applied. For large-scale roll out we need to consider which
are the most helpful and cost-effective at which stage of the ill-
ness and to which individuals. This requires knowledge of how
service users ascribe value to different outcomes and treatments
as well as which individuals are likely to benefit the most from
different treatments to produce a coherent mental health recov-
ery programme. Tailoring treatment requires an understanding
of adherence requirements as well as therapeutic interactions to
explain how therapy fits with the service users’ personal goals. Not
all information for making these clinical decisions is embedded in
any database so the burden on research is to provide enough infor-
mation to signal to health professionals the best course of action.
More research on dissemination of treatment approaches as well
as training and supervision requirements is needed in the form of
dissemination science if patients with a diagnosis of schizophrenia
are to receive the best intervention programme.
Disclosure of interest The author has not supplied his declaration
of competing interest.
SA02
Nutrition, sleep, physical exercise:
Impact on mental health
W. Rössler
University of Zurich, Psychiatric University Hospital, Zürich,
Switzerland
Until recently nutrition and various other lifestyle factors were
predominantly in the focus of medical disciplines like cardiology,
endocrinology or gastroenterology. As mental disorders are mul-
tifactorial diseases and as such are complex, emerging evidence
suggests that nutrition, exercise and sleep also play an important
role in the aetiology, progression and treatment of mental disor-
ders. In this regard research has mostly focused on depression and
anxiety, but there is also evidence for other mental disorders like
schizophrenia or autism. Some details concerning the relationship
between diet and sleep on neuro-transmitter processes, immune-
inflammatory pathways or oxidative stress will be demonstrated.
Modifications of life style factors and diet are increasingly
recognized as potential therapeutic options. Mostly used are
nutrient-based supplements and essential elements in combina-
tion. But also healthy diet patterns with a high intake of vegetable,
fruits and fish have proven beneficial in the treatment. If we better
understand the microbiota-gut-brain axis and its impact on behav-
ior, mood and cognitive processes, diet and lifestyle factors can
not only contribute to the treatment but also to the prevention of
mental disorders.
Disclosure of interest The author has not supplied his declaration
of competing interest.
Drinking patterns we should accept while
reducing harmful alcohol consumption
SA03
Can alcohol-dependent patients really
reduce their alcohol consumption
over time?
K. Mann
Central Institute of Mental Health, Medical Faculty Mannheim,
University of Heidelberg, Addiction Research, Mannheim, Germany
Introduction Treatment of alcohol dependent patients is moder-
ately successful but it only reaches about 10% of the population in
need. A new harm reduction strategy aims at abstinence in the long
run but claims to benefit patients already early on by reducing their
alcohol consumption.
Objectives A brief outline of the debate on abstinence versus con-
trolled drinking will be followed reporting several RCTs striving for
reduced drinking in alcohol dependent patients.
Aims The participant will find guidancewhether and how to treat
patients following this new approach.
Results Studies testing behavioural treatments and counselling
(MATCH, UKATT) indicate that a reduction over time is possible.
Using nalmefene (a mu and delta opioid antagonist and a partial
agonist) RCTs withmore than 2500 patients were performed show-
ing a benefit over placebo. On this basis the EMA approved this
drug for the reduction of alcohol consumption in alcohol dependent
0924-9338/$ – see front matter